Br J Cancer: Comprehensive analysis of 21 gene recurrence scores in patients with immersive breast catheter cancer accompanied by in-place catheter cancer

Breast catheter in-place cancer (DCIS) is a non-invasive disease of the breast that can be treated with different strategies.
DCIS is a precursor to most immersive breast cancers, although it is not immediately life-threatening.
previous studies have shown that approximately 20.6 to 45.5% of immersive breast catheterized cancer (IDC) is associated with DCIS (IDC/DCIS).
21 gene recurrence score (RS) analysis is now widely used to assess the risk of disease recurrence in patients with early-stage immersive breast cancer.
The American Society of Clinical Oncology (ASCO) and the National Journal of General Medicine Cancer Network (NCCN) browsing guidelines now recommend the use of 21 gene recurrence scoring algorithms in patients with early-stage immersive breast cancer who are ER (estrogen-positive) positive and HER2 (human skin growth factor-like 2) negative.
, however, it is unclear whether IDC/DCIS affects the 21 gene recurrence scoring algorithm.
21 gene recurrence score analysis in IDC or IDC/DCIS breast cancer patients in this study, the researchers analyzed ER-positive, HER2-negative N0-1 patients using 21 gene recurrence scoring algorithms.
the patients were divided into pure IDC and IDC/DCIS groups with DCIS, and the expression of 16 cancer genes and the prognosticity of the patients were analyzed by comparing the RS scores of patients in the IDC and IDC/DCIS groups.
1,458 patients with 16 cancer genes in IDC or IDC/DCIS breast cancer patients, 320 of them with DCIS.
studies have shown that IDC/DCIS is associated with lower RS.
risk RS or medium risk RS are more common in IDC/DCIS patients.
analysis of individual genes in RS scoring algorithms, in IDC/DCIS patients, the expression levels of Ki67, CCNB1 and MYBL2 associated with cell proliferation, as well as MMP11 and CTSL2 associated with cell invasion, were significantly lower than in patients in the pure IDC group.
further studies have shown that in IDC/DCIS patients, lower RS is associated with higher DCIS ratios and lower DCIS levels.
31 months of the medium follow-up time, DCIS in IDC did not significantly affect the patient's prognostics.
, the study showed that IDC/DCIS was associated with a lower 21 gene recurrence score, which may be associated with lower expression levels of genes associated with cell proliferation and invasion.
and grade of DCIS can affect the 21 gene recurrence scores in IDC/DCIS patients.
the relatively short follow-up time and low recurrence rate, further assessment of IDC/DCIS effects on patient prognostication is required.
。